Profile data is unavailable for this security.
About the company
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
- Revenue in USD (TTM)0.00
- Net income in USD-274.18m
- Incorporated2019
- Employees108.00
- LocationNeumora Therapeutics Inc490 Arsenal Way, Suite 200WATERTOWN 02472United StatesUSA
- Phone+1 (857) 760-0900
- Fax+1 (302) 655-5049
- Websitehttps://neumoratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | 288.00k | -228.06m | 1.96bn | 96.00 | -- | 4.98 | -- | 6,815.50 | -4.25 | -4.25 | 0.0053 | 8.29 | 0.0006 | -- | 5.65 | 3,063.83 | -48.67 | -55.59 | -52.32 | -60.32 | -- | -- | -79,185.77 | -5,678.12 | -- | -- | 0.0372 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Disc Medicine Inc | 0.00 | -91.00m | 1.98bn | 74.00 | -- | 4.05 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Mirum Pharmaceuticals Inc | 264.38m | -109.16m | 1.99bn | 294.00 | -- | 8.64 | -- | 7.51 | -2.40 | -2.40 | 5.81 | 4.81 | 0.4788 | 5.06 | 5.52 | 1,001,424.00 | -19.77 | -38.93 | -23.38 | -44.88 | 72.27 | -- | -41.29 | -190.71 | 3.09 | -- | 0.573 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| MannKind Corp | 267.20m | 21.57m | 1.99bn | 414.00 | 101.52 | -- | 70.59 | 7.43 | 0.0711 | 0.0711 | 0.9277 | -0.7612 | 0.6812 | 2.79 | 13.36 | 645,410.60 | 5.50 | -26.07 | 7.00 | -37.80 | 71.91 | 59.68 | 8.07 | -57.61 | 4.17 | 1.89 | 1.77 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Nurix Therapeutics Inc | 56.42m | -176.98m | 1.99bn | 284.00 | -- | 5.01 | -- | 35.33 | -2.91 | -2.91 | 0.9222 | 5.62 | 0.1373 | -- | -- | 198,676.10 | -43.07 | -33.01 | -52.51 | -39.66 | -- | -- | -313.65 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Spyre Therapeutics Inc | 0.00 | -214.90m | 2.00bn | 60.00 | -- | 11.79 | -- | -- | -7.44 | -7.44 | 0.00 | 6.37 | 0.00 | -- | -- | 0.00 | -68.40 | -101.87 | -81.72 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Fortrea Holdings Inc | 2.88bn | -228.20m | 2.04bn | 16.00k | -- | 1.39 | -- | 0.7087 | -2.56 | -3.23 | 32.30 | 16.33 | 0.7262 | -- | 3.48 | 159,794.40 | -5.76 | -- | -7.11 | -- | 17.17 | -- | -7.93 | -- | -- | -0.3374 | 0.4348 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -274.18m | 2.18bn | 108.00 | -- | 5.72 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.21bn | 136.00 | -- | 2.40 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Azenta Inc | 658.62m | -156.38m | 2.24bn | 3.30k | -- | 1.16 | -- | 3.40 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 2.25bn | 500.00 | -- | 4.27 | -- | 34.48 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Akero Therapeutics Inc | 0.00 | -204.18m | 2.29bn | 61.00 | -- | 2.87 | -- | -- | -3.41 | -3.41 | 0.00 | 11.53 | 0.00 | -- | -- | 0.00 | -26.71 | -37.73 | -27.66 | -40.13 | -- | -- | -- | -- | -- | -- | 0.042 | -- | -- | -- | -35.46 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.48 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 2.39bn | 266.00 | -- | -- | -- | 21.66 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
Data as of Nov 12 2024. Currency figures normalised to Neumora Therapeutics Inc's reporting currency: US Dollar USD
19.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 5.10m | 3.19% |
| MIC Capital Management UK LLPas of 30 Jun 2024 | 4.46m | 2.79% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.06m | 2.54% |
| ICONIQ Capital LLCas of 30 Jun 2024 | 3.40m | 2.12% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.13m | 1.96% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 3.00m | 1.87% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 2.82m | 1.77% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 2.07m | 1.29% |
| Avidity Partners Management LPas of 30 Jun 2024 | 1.80m | 1.13% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.29m | 0.80% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
